Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2.

Adoptive immunotherapy with lymphokine activated killer (LAK) cells and recombinant interleukin-2 (IL-2) is successful in a variety of tumour models in both the normal and the immunocompromised mouse. We investigated the effects of an immune response to an allogeneic challenge on the metabolism of I...

Descripción completa

Detalles Bibliográficos
Autores principales: Eggermont, A. M., Steller, E. P., Matthews, W., Sugarbaker, P. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002132/
https://www.ncbi.nlm.nih.gov/pubmed/2444243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002132/
https://www.ncbi.nlm.nih.gov/pubmed/2444243

Ejemplares similares